<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02544607</url>
  </required_header>
  <id_info>
    <org_study_id>2015P001912</org_study_id>
    <secondary_id>24032</secondary_id>
    <nct_id>NCT02544607</nct_id>
  </id_info>
  <brief_title>Ketamine for Depression: An MRI Study</brief_title>
  <official_title>Baseline Insular Dysfunction as a Predictor of Ketamine's Antidepressant Effects in Anxious Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brain &amp; Behavior Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ketamine has been shown to decrease symptoms of anxious depression quickly. This decrease has
      been shown to last for up to one month. MRI technology will be used before and after ketamine
      for patients with depression to examine the extent to which certain brain areas predict
      ketamine's antidepressant effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ketamine's antidepressant effects were measured with Hamilton Depression Rating Scale (HDRS).
      MRI data will also be analyzed to examine the extent to which certain brain areas predict
      ketamine's antidepressant effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">December 29, 2017</completion_date>
  <primary_completion_date type="Actual">December 29, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hamilton Depression Rating Scale (HDRS) From Baseline/Minute 0 to 4 Hours Post-infusion.</measure>
    <time_frame>4 hours</time_frame>
    <description>Hamilton Depression Rating Scale; possible scores range from 0 to 81 with higher scores indicating higher depression symptoms
Change will be calculated by difference between HDRS from Minute 0 to Minute 240.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Tissue Fractional Anisotropy Quantification (Left Inferior Longitudinal Fasciculus)</measure>
    <time_frame>4 hours</time_frame>
    <description>Free-water imaging, a two-compartment diffusion model, was employed to quantify tissue fractional anisotropy (FAt) pre- and post-infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Tissue Fractional Anisotropy Quantification (Right Inferior Longitudinal Fasciculus)</measure>
    <time_frame>4 hours</time_frame>
    <description>Free-water imaging, a two-compartment diffusion model, was employed to quantify tissue fractional anisotropy (FAt) pre- and post-infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Tissue Fractional Anisotropy Quantification (Left Superior Longitudinal Fasciculus)</measure>
    <time_frame>4 hours</time_frame>
    <description>Free-water imaging, a two-compartment diffusion model, was employed to quantify tissue fractional anisotropy (FAt) pre- and post-infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Tissue Fractional Anisotropy Quantification (Right Uncinate Fasciculus)</measure>
    <time_frame>4 hours</time_frame>
    <description>Free-water imaging, a two-compartment diffusion model, was employed to quantify tissue fractional anisotropy (FAt) pre- and post-infusion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Depression</condition>
  <condition>Anxious Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Ketamine + MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All eligible participants will receive open label ketamine and undergo Magnetic Resonance Imaging (MRI).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine 0.5mg/kg over 40 minutes IV</description>
    <arm_group_label>Ketamine + MRI</arm_group_label>
    <other_name>Ketamine Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Magnetic Resonance Imaging (MRI)</intervention_name>
    <description>MRI technology will be used before and after ketamine for patients with depression</description>
    <arm_group_label>Ketamine + MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Patients with Depression

        Patients will:

          1. be 18-64 years old,

          2. read, understand, and provide written informed consent in English,

          3. meet criteria for a primary psychiatric diagnosis of major depressive disorder for ≥ 4
             weeks,

          4. have a history of ≥1 failed medication trial during the current depression

          5. be on a stable antidepressant and psychotherapy regimen for ≥28 days,

          6. maintain a treating doctor who is in agreement with study participation,

          7. have a reliable chaperone accompany them home following the completion of the ketamine
             infusion day,

          8. be generally healthy, as assessed by medical history, physical examination (including
             vital signs), clinical laboratory evaluations, and electrocardiogram (EKG),

          9. be of non-childbearing potential or use of an acceptable form of birth control
             (females only),

         10. be right handed.

        Exclusion Criteria: Patients with Depression

        Patients will be excluded if any of the following criteria are met:

        1) delirium or dementia diagnosis, 2) unstable medical illness or clinically significant
        laboratory results, 3) history of clinically significant cardiovascular disease or
        electrocardiogram (EKG) findings, or medical conditions that put the patient at risk for
        possible cardiac side effects or alter brain morphology (e.g., traumatic brain injury), 4)
        history of multiple adverse drug reactions, 5) current/past history of psychotic disorders,
        6) active substance use disorders (except nicotine and caffeine) within the past six months
        or past history of ketamine/PCP abuse, 7) requirement of excluded medications that may
        interact with ketamine, 8) weigh &gt;250 lbs., 9) pregnancy, breastfeeding, or unacceptable
        means of birth control (females only) 10) presence of MRI contraindications (e.g., presence
        of metallic (ferromagnetic) implants (e.g., heart pacemaker, aneurysm clips)), 11) current
        serious suicidal or homicidal risk, or 12) concurrent participation in other research
        studies.

        ---------------------------------------------------------------------------------------

        Inclusion Criteria: Healthy Controls

        Healthy Controls will:

          1. be 18-64 years old,

          2. read, understand, and provide written informed consent in English,

          3. have a reliable chaperone accompany them home following the completion of the ketamine
             infusion day,

          4. be generally healthy, as assessed by medical history, physical examination (including
             vital signs), clinical laboratory evaluations, and electrocardiogram (EKG),

          5. be of non-childbearing potential or use of an acceptable form of birth control
             (females only), and

          6. be right handed.

        Exclusion Criteria: Healthy Controls

        Healthy controls will be excluded if any of the following criteria are met:

          1. current or past psychiatric diagnosis (excluding phobias), including alcohol or
             substance abuse or dependence diagnosis (except for nicotine or caffeine),

          2. presence of MRI contraindications (e.g., presence of metallic (ferromagnetic) implants
             (e.g., heart pacemaker, aneurysm clips)),

          3. presence of medical illness likely to alter brain morphology and/or physiology (e.g.,
             traumatic brain injury),

          4. requirement of excluded medications that may interact with ketamine,

          5. presence of psychiatric disorders in first-degree relatives,

          6. pregnancy, breastfeeding, or unacceptable means of birth control (females only), or

          7. weight &gt;250 lbs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristina Cusin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MGH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.depressionmgh.org/our-studies</url>
    <description>MGH Depression Clinical and Research Program</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>September 4, 2015</study_first_submitted>
  <study_first_submitted_qc>September 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2015</study_first_posted>
  <results_first_submitted>August 14, 2018</results_first_submitted>
  <results_first_submitted_qc>March 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 4, 2019</results_first_posted>
  <last_update_submitted>April 3, 2019</last_update_submitted>
  <last_update_submitted_qc>April 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Cristina Cusin, MD</investigator_full_name>
    <investigator_title>Cristina Cusin, M.D.</investigator_title>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>Depression</keyword>
  <keyword>Anxious Depression</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 9, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT02544607/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>As specified, the total number of participants enrolled are those who agreed to participate in the study following completion of the informed consent process (n=25). This number does not reflect the number of subjects who actually started treatment (n=16).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ketamine + MRI</title>
          <description>All eligible participants will receive open label ketamine and undergo Magnetic Resonance Imaging
Ketamine: Ketamine 0.5mg/kg over 40 minutes IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine</title>
          <description>All eligible participants will receive open label ketamine
Ketamine: Ketamine 0.5mg/kg over 40 minutes IV</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Hamilton Depression Rating Scale (HDRS) From Baseline/Minute 0 to 4 Hours Post-infusion.</title>
        <description>Hamilton Depression Rating Scale; possible scores range from 0 to 81 with higher scores indicating higher depression symptoms
Change will be calculated by difference between HDRS from Minute 0 to Minute 240.</description>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>All eligible participants will receive open label ketamine
Ketamine: Ketamine 0.5mg/kg over 40 minutes IV</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hamilton Depression Rating Scale (HDRS) From Baseline/Minute 0 to 4 Hours Post-infusion.</title>
          <description>Hamilton Depression Rating Scale; possible scores range from 0 to 81 with higher scores indicating higher depression symptoms
Change will be calculated by difference between HDRS from Minute 0 to Minute 240.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.625" lower_limit="-25" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Tissue Fractional Anisotropy Quantification (Left Inferior Longitudinal Fasciculus)</title>
        <description>Free-water imaging, a two-compartment diffusion model, was employed to quantify tissue fractional anisotropy (FAt) pre- and post-infusion</description>
        <time_frame>4 hours</time_frame>
        <population>Reasons for missing data (N=3) included a scanner malfunction and participant requests to stop scanning prior to dMRI sequence acquisition.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine + MRI</title>
            <description>All eligible participants will receive open label ketamine and undergo Magnetic Resonance Imaging (MRI).
Ketamine: Ketamine 0.5mg/kg over 40 minutes IV
Magnetic Resonance Imaging (MRI): MRI technology will be used before and after ketamine for patients with depression</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Tissue Fractional Anisotropy Quantification (Left Inferior Longitudinal Fasciculus)</title>
          <description>Free-water imaging, a two-compartment diffusion model, was employed to quantify tissue fractional anisotropy (FAt) pre- and post-infusion</description>
          <population>Reasons for missing data (N=3) included a scanner malfunction and participant requests to stop scanning prior to dMRI sequence acquisition.</population>
          <units>percent change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Tissue Fractional Anisotropy Quantification (Right Inferior Longitudinal Fasciculus)</title>
        <description>Free-water imaging, a two-compartment diffusion model, was employed to quantify tissue fractional anisotropy (FAt) pre- and post-infusion</description>
        <time_frame>4 hours</time_frame>
        <population>Reasons for missing data (N=3) included a scanner malfunction and participant requests to stop scanning prior to dMRI sequence acquisition.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine + MRI</title>
            <description>All eligible participants will receive open label ketamine and undergo Magnetic Resonance Imaging (MRI).
Ketamine: Ketamine 0.5mg/kg over 40 minutes IV
Magnetic Resonance Imaging (MRI): MRI technology will be used before and after ketamine for patients with depression</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Tissue Fractional Anisotropy Quantification (Right Inferior Longitudinal Fasciculus)</title>
          <description>Free-water imaging, a two-compartment diffusion model, was employed to quantify tissue fractional anisotropy (FAt) pre- and post-infusion</description>
          <population>Reasons for missing data (N=3) included a scanner malfunction and participant requests to stop scanning prior to dMRI sequence acquisition.</population>
          <units>percent change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Tissue Fractional Anisotropy Quantification (Left Superior Longitudinal Fasciculus)</title>
        <description>Free-water imaging, a two-compartment diffusion model, was employed to quantify tissue fractional anisotropy (FAt) pre- and post-infusion</description>
        <time_frame>4 hours</time_frame>
        <population>Reasons for missing data (N=3) included a scanner malfunction and participant requests to stop scanning prior to dMRI sequence acquisition.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine + MRI</title>
            <description>All eligible participants will receive open label ketamine and undergo Magnetic Resonance Imaging (MRI).
Ketamine: Ketamine 0.5mg/kg over 40 minutes IV
Magnetic Resonance Imaging (MRI): MRI technology will be used before and after ketamine for patients with depression</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Tissue Fractional Anisotropy Quantification (Left Superior Longitudinal Fasciculus)</title>
          <description>Free-water imaging, a two-compartment diffusion model, was employed to quantify tissue fractional anisotropy (FAt) pre- and post-infusion</description>
          <population>Reasons for missing data (N=3) included a scanner malfunction and participant requests to stop scanning prior to dMRI sequence acquisition.</population>
          <units>percent change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.0499</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Tissue Fractional Anisotropy Quantification (Right Uncinate Fasciculus)</title>
        <description>Free-water imaging, a two-compartment diffusion model, was employed to quantify tissue fractional anisotropy (FAt) pre- and post-infusion</description>
        <time_frame>4 hours</time_frame>
        <population>Reasons for missing data (N=3) included a scanner malfunction and participant requests to stop scanning prior to dMRI sequence acquisition.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine + MRI</title>
            <description>All eligible participants will receive open label ketamine and undergo Magnetic Resonance Imaging (MRI).
Ketamine: Ketamine 0.5mg/kg over 40 minutes IV
Magnetic Resonance Imaging (MRI): MRI technology will be used before and after ketamine for patients with depression</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Tissue Fractional Anisotropy Quantification (Right Uncinate Fasciculus)</title>
          <description>Free-water imaging, a two-compartment diffusion model, was employed to quantify tissue fractional anisotropy (FAt) pre- and post-infusion</description>
          <population>Reasons for missing data (N=3) included a scanner malfunction and participant requests to stop scanning prior to dMRI sequence acquisition.</population>
          <units>percent change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected throughout the course of the study. The collection of this data took place at the initial screen, continuously throughout the duration of the administration visit (e.g. Visit 2), 24 hours post-administration, and up to 3 months following the administration visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ketamine</title>
          <description>All eligible participants will receive open label ketamine
Ketamine: Ketamine 0.5mg/kg over 40 minutes IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>bilateral nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Cristina Cusin</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-6421</phone>
      <email>ccusin@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

